EpiQuin Micro Approved for Treatment of Skin Discoloration
SkinMedica Inc. of San Diego announced today the launch of EpiQuin Micro, a 4-percent hydroquinone topical cream indicated for the gradual treatment of ultraviolet-induced skin discoloration resulting from pregnancy, hormone replacement therapy, skin trauma, or the use of oral contraceptives.
According to SkinMedica, the hydroquinone component of EpiQuin Micro acts as a bleaching agent that lightens dark skin patches and limits the overproduction of melanin. The product also contains retinol, and vitamins C and E, which the company said can "enhance the health and appearance of aging skin."
According to the product's labeling, the topical cream should be applied to affected skin once in the morning and again at bedtime, or as directed by a physician. Minor redness may occur at the site of administration but is not a reason to stop using the product.
Use of the product should be discontinued if itching, vesicle formation, or excessive inflammation occurs at the application site. People who are hypersensitive to sulfites should not use EpiQuin Micro, which contains sodium metabisulfite.
No effective dosage of the product has been established for children 12 years of age or younger.
The product's labeling notes that exposure to sunlight can reverse the effects of hydroquinone and should be avoided through the use of a sunscreen or protective clothing.
EpiQuin Micro is supplied in 30-g tubes. A company spokeswoman said that Cardinal Health Inc. is the product's sole distributor.